Psychopharmacology of depression and sexual disorders
Abstract
Sexual dysfunctions as side effects of antidepressant treatments are being reported more and more frequently: they are one of the main reasons of dropout from therapy. These side effects are reported in between 20% and 40% of cases. The aim of this study is to highlight, following the actual evidence from the field of psychopharmacology, how these side effects may not be directly related to the antidepressant treatment; on the contrary we show that, following the observational clinical data obtained in our Mental Health Dept., a careful clinical interview about the sexual behaviour of the patients allows psychotherapy to interact with pharmacotherapy, in order to reduce the drug dosage, or replace it with another drug, and/or to combine an erectile dysfunction treatment with the psychopharmacological therapy. This careful clinical interview about the sexual behavior of the patients will more clearly determine the percentages of sexual dysfunction side effects, and also avoid drop-out from antidepressant therapy.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Combining in silico and in vitro approaches to identification of potent inhibitor against phospholipase A2 (PLA2)
- In silico and in vitro studies: investigating the chemical composition, DFT, molecular docking, and dynamic simulation of Satureja candidissima (Munby) Briq essential oil as a potential antibacterial agent
- Quercetin combined with ciprofloxacin and gentamicin inhibits biofilm formation and virulence in Staphylococcus aureus
- In silico study of the mechanism of action, pharmacokinetic and toxicological properties of some N-methylanthranilates and their analogs
- Anticonvulsant Effects of Citronellal, Daidzin, and Phytol, Possibly Through GABAA Receptor and Voltage-Gated Sodium Channel Interaction Pathways: In Vivo and In Silico Studies
- 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as D3R-Selective Ligands for 3D-QSAR, Docking and Molecular Dynamics Simulation Studies
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.